In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.
CAR T therapy has yet to be translated for T cell derived leukemias. One study leaves room for hope, as their CAR T product demonstrates early proof-of-concept.
Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.
At the 2023 American Society for Clinical Oncology Annual Meeting to be held June 2-6 in Chicago, Illinois Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.
Research, Science and Innovation Minister Dr Ayesha Verrall and the Chinese Minister of Science and Technology Wang Zhigang met in Wellington today and affirmed the two countries' long-standing science relationship. Minister Wang was in New Zealand for the 6th New Zealand-China Joint Commission Meeting on Science and Technology Cooperation. Following their meeting the ministers toured the Malaghan Institute of Medical Research at Victoria University Wellington. The Malaghan Institute has a joint venture with China's Hunan Zhaotai Medical Group to develop a new approach to fighting cancer called Car T-cell therapy. "China is one of our key science and innovation partners and Minister Wang and I confirmed our commitment to this strong relationship," Ayesha Verrall said. "We have significant mutual research interests, particularly in food, environmental and health sciences. New Zealand and Chinese scientists have been cooperating for more than 40 years and each year